Skip to Content

Ocrelizumab Dosage

Medically reviewed on December 26, 2017.

Applies to the following strengths: 300 mg/10 mL

Usual Adult Dose for Multiple Sclerosis

Initial dose: 300 mg IV followed 2 weeks later by a second 300 mg IV infusion
Maintenance dose: 600 mg IV every 6 months

Manufacturer recommended infusion rates (consult manufacturer product information for more information):
-Infusions 1 and 2 (300 mg of this drug in 250 mL 0.9% sodium chloride injection): Start at 30 mL/hr and increase by 30 mL/hr every 30 minutes to a maximum of 180 mL/hr; duration of 2.5 hours or longer
-Subsequent infusions (600 mg of this drug in 500 mL 0.9% sodium chloride injection): Start at 40 mL/hr and increase by 40 mL/hr every 30 minutes to a maximum of 200 mL/hr; duration of 3.5 hours or longer

-The patient should be premedicated with methylprednisolone (or an equivalent corticosteroid) 100 mg IV approximately 30 minutes prior to each infusion and an antihistamine (e.g., diphenhydramine) approximately 30 to 60 minutes prior to each infusion; the addition of an antipyretic (e.g., acetaminophen) may also be considered.
-The patient should be observed for at least one hour after the completion of the infusion.
-If a planned infusion is missed, administer it as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses must be separated by at least 5 months.

Use: For the treatment of patients with relapsing or primary progressive forms of multiple sclerosis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

-Mild to moderate infusion reactions: Reduce the infusion rate to half the rate at the onset of the infusion reaction and maintain the reduced rate for at least 30 minutes; if this rate is tolerated, increase the rate as normal (this change in rate will increase the total duration of the infusion but not the total dose)
-Severe infusion reactions: Interrupt the infusion and administer supportive treatment; restart the infusion after all symptoms have resolved; when restarting, begin at half of the infusion rate at the time of onset of the infusion reaction; if this rate is tolerated, increase the rate as normal (this change in rate will increase the total duration of the infusion but not the total dose)
-Life-threatening infusion reactions: Stop the infusion and permanently discontinue this drug; provide appropriate supportive treatment


This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Visually inspect the solution for particulate matter and discoloration prior to administration; do not use the solution if discolored or if the solution contains discrete foreign particulate matter.
-Do not shake.

Storage requirements:
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
-This drug should be prepared by a healthcare professional using aseptic technique.

IV compatibility:
-This drug can be mixed with 0.9% sodium chloride injection. Other diluents should not be used.

-Prior to initiating therapy with this drug, the patient should be screened for hepatitis B (HPV). For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during therapy.
-Because vaccination with live or live-attenuated vaccines is not recommended during therapy with this drug and after discontinuation until B-cell repletion, administer all necessary immunizations according to immunization guidelines at least 6 weeks prior to initiation of therapy.
-Prior to every infusion of this drug, determine whether there is an active infection; in case of active infection, delay the infusion of until the infection is resolved.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.